Gefitinib

證據等級: L5

預測適應症: 10 個

Gefitinib: From Non-Small Cell Lung Cancer to Gingival Fibromatosis (Low-Confidence Signal)

One-Sentence Summary

Gefitinib is an oral EGFR tyrosine kinase inhibitor established for EGFR-mutant non-small cell lung cancer (NSCLC), as confirmed by the literature embedded in this evidence pack. The TxGNN model's top-ranked new indication, Gingival Fibromatosis, has no supporting clinical trials or literature and no known mechanistic link to EGFR biology — the pack's own rationale flags this as a likely embedding-space artifact rather than a genuine drug-specific signal. Across all 10 predicted indications in this candidate set, only two (lung hilum carcinoma, pulmonary sulcus neoplasm — both anatomical subtypes of NSCLC) carry any literature relevance, and even those represent label-adjacent extensions rather than novel repurposing.

Quick Overview

Item	Content
Original Indication	Not present in regulatory license data (drug not marketed in Germany); consistently described in the pack's own literature as therapy for EGFR-mutant non-small cell lung cancer (NSCLC)
Predicted New Indication	Gingival Fibromatosis
TxGNN Prediction Score	99.89% (rank 1785 in model's internal ranking)
Evidence Level	L5 (model prediction only, no trials or literature)
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal DrugBank MOA data is flagged as a blocking data gap (DG002) in this evidence pack. Based on literature embedded in the pack itself (e.g., PMID 24794908, 12841190), gefitinib is a selective, ATP-competitive small-molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, used clinically to treat EGFR-mutant NSCLC by blocking downstream proliferation and survival signaling in tumor cells.

For the top-ranked prediction, gingival fibromatosis, there is no mechanistic bridge to this pathway. Gingival fibromatosis is a gingival connective-tissue overgrowth disorder linked to pathways such as TGF-β/fibroblast proliferation, not EGFR-driven epithelial malignancy. The repurposing rationale attached to this candidate explicitly states the high TxGNN score likely reflects clustering in the model's disease-embedding space rather than a drug-specific pharmacological signal.

Within the broader candidate set, the only two predictions with a coherent mechanistic story are lung hilum carcinoma (rank 5, L3) and pulmonary sulcus neoplasm / Pancoast tumor (rank 9, L4) — both are anatomical subtypes of NSCLC, gefitinib's already-approved indication. These are not novel repurposing hypotheses so much as label-adjacent anatomical extensions, and the attached evidence (a single case report, an ECOG NSCLC-stage review, an unrelated leptomeningeal metastasis case) does not specifically address these subtypes. The remaining 7 candidates (fibroma of lung, hamartoma of lung, IBMPFD, lung benign neoplasm, a rare genetic syndrome, lung germ cell tumor, junctional epidermolysis bullosa) show either mechanistic implausibility, literature-label mismatch, or in the case of junctional epidermolysis bullosa, a mechanism running in the opposite direction (EGFR inhibition is a known cause of skin barrier toxicity, not a treatment for a skin barrier defect).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Germany Market Information

Gefitinib currently has no marketing authorizations on file in Germany (market status: not marketed, total licenses: 0). No product table can be generated from this evidence pack.

Cytotoxicity

Gefitinib is an antineoplastic agent (EGFR-targeted therapy for NSCLC, per literature embedded in this pack), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (EGFR tyrosine kinase inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Low. Literature in this pack highlights interstitial lung disease (PMID 20942679, 20949670), QT prolongation (PMID 34474028, 37258113), and cutaneous toxicity (PMID 18931563) as characteristic adverse effects, rather than bone-marrow suppression typical of cytotoxic chemotherapy
Emetogenicity Classification	Low (oral small-molecule targeted agent)
Monitoring Items	Liver function tests, pulmonary symptoms/imaging (ILD risk), ECG/QTc, skin toxicity assessment; baseline CBC reasonable given oncologic use
Handling Protection	Gefitinib is an oral antineoplastic and typically appears on institutional hazardous-drug lists; standard oral hazardous-drug handling precautions apply, though it does not require IV cytotoxic reconstitution/compounding controls

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/German warnings and contraindications data is a blocking data gap — DG001 — and drug-drug interaction search returned no results in this pack.)

Conclusion and Next Steps

Decision: Hold

Rationale: None of the 10 predicted indications in this candidate set is supported by adequate mechanistic or clinical evidence: 8 of 10 are L5 (model score only, no trials/literature) or mechanistically implausible/mismatched, and the two with any literature support (lung hilum carcinoma, pulmonary sulcus neoplasm) are anatomical subtypes of gefitinib's existing NSCLC indication rather than genuine new repurposing opportunities. Combined with a blocking safety data gap (DG001) and the drug's unmarketed status in Germany, this candidate does not meet the bar to advance past S0/S1.

To proceed, the following is needed:

Resolve DG001: obtain TFDA/EU SmPC warnings and contraindications for gefitinib (Iressa)
Resolve DG002: confirm formal MOA via DrugBank API rather than literature inference
If pursuing lung hilum carcinoma or pulmonary sulcus neoplasm, clarify with regulatory/clinical review whether these are already covered under the existing NSCLC label — a "new indication" claim may not be warranted
Re-screen or manually curate the TxGNN top-10 output before pharmacist review, given the high proportion of mechanistically implausible or label-mismatched candidates (rare genetic syndromes, benign tumors, and a barrier-defect skin disease paired with an EGFR inhibitor)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.